A subset of over-expressed microRNAs (miRNAs) identified in parathyroid carcinomas (Ca) compared to normal glands belongs to C19MC, a cluster on chromosome 19q13.4 involved in stem cell biology and tumourigenesis. In this study, the expression of C19MC-MIR371-3 clusters and the molecular mechanisms presiding their modulation were investigated in a series of six normal parathyroids, 24 adenomas (Ad), 15 Ca and five matched metastases. The general expression levels of C19MC or MIR371-3 clusters in Ad lesions did not differ from normal glands, while they distinguished Ad from Ca at unsupervised hierarchical cluster analysis (PZ0 . 0008). MIR517C showed the most significant difference in expression between Ca and Ad (PZ0 . 0003) and it positively correlated with serum calcium, parathormone and tumour weight. In regard to the molecular mechanism determining C19MC cluster activation, we could detect C19MC copy number (CN) gain in ten Ca (67%) extending distal to the MIR371-3 cluster in almost all samples. Conversely, only four Ad (16%) showed C19MC amplification, with one case presenting distal genomic aberration to MIR371-3. Globally, CN variations of 19q13.4 loci were significantly associated with MIR517C up-regulation (PZ0 . 006). Opposite to normal glands where C19MC promoter was methylated, hypomethylation occurred in 15 out of 30 analysed tumours. Though the epigenetic status did not correlate with C19MC miRNA expression levels, loss of C19MC promoter methylation was significantly associated with Ca and metastatic disease (PZ0 . 01). In conclusion, C19MC cluster aberrations are a characteristic of Ca with respect to Ad. Altogether, these evidences point towards a role for 19q13.4 miRNA clusters as oncogenes in parathyroid tumourigenesis.
Introduction
Primary hyperparathyroidism is a common endocrine disorder in post-menopausal women. Parathormone (PTH) hypersecretion is sustained by a single parathyroid adenoma (Ad) in the majority of cases, while parathyroid carcinomas (Ca) are rare (!5% of cases) and invariably lethal. Though germ-line or somatic inactivating mutations of oncosuppressor genes (CDC73/HRPT2 and MENIN) frequently occur in parathyroid tumours, the molecular mechanisms of parathyroid tumourigenesis are still largely unknown.
MicroRNAs (miRNAs) are small, endogenously expressed non-protein coding RNAs (w19-23 nt in length) that regulate gene expression. miRNAs interact with a huge number of target messenger RNAs and are recognised as key regulators of a broad range of cellular and developmental processes (Bushati & Cohen 2007) . Recent evidence indicates that alterations in miRNA genes play a critical role in cancer initiation and progression (Calin & Croce 2007) .
Recently, we produced data showing an altered miRNA expression pattern in parathyroid cancers compared with normal parathyroid tissue (Corbetta et al. 2010) . Among the identified over-expressed miRNAs (nZ16), a subset (50%) belonged to the primate-specific miRNA cluster C19MC mapping to chromosome 19q13.4. The 100 kb long C19MC cluster with 46 tandemly repeated miRNA genes encoding for 59 mature miRNAs is the largest cluster discovered so far in humans and accounts for about 8% of all known human miRNA genes (Bortolin-Cavaille et al. 2009 ). The large C19MC cluster shares a similar seed sequence with the closely distal MIR371-3 cluster, which is much smaller, spanning a region of w1050 bp where four genes encode for seven mature miRNAs (Laurent et al. 2008) . Reports recently described that members of the C19MC or MIR371-3 clusters are expressed by human embryonic stem cells (hESCs; Laurent et al. 2008 , Li et al. 2009b , Ren et al. 2009 ) and over-expressed by human cancers (Toffanin et al. 2011) . Activation of both clusters might be a general phenomenon in human tumourigenesis, as rearrangements of 19q13.4, genomic amplification and methylation abnormalities including the C19MC locus have been frequently found in several human neoplasias (Li et al. 2009a , Rippe et al. 2010 , Toffanin et al. 2011 . Finally, two members of the C19MC cluster, namely MIR517C and 520G, were shown to act as oncogenes, by promoting disease development in animal models (Li et al. 2009a) .
In this study, we identified a selective over-expression of a specific miRNA belonging to the C19MC cluster, namely MIR517C, in parathyroid Ca compared with benign Ad and normal tissues. Moreover, the expression pattern of C19MC and MIR371-3 cluster members was consistent with genomic amplification of 19q13.41 in the majority of parathyroid Ca. Finally, C19MC promoter demethylation was associated with the presence of invasive tumour (parathyroid Ca) and metastatic disease. These data point to a potential oncogenic role for C19MC miRNAs in parathyroid tumourigenesis.
Materials and methods

Parathyroid tissue samples
Paraffin-embedded samples from 15 parathyroid Ca and five matched metastasis, 24 parathyroid Ad and six normal parathyroid glands incidentally removed from normocalcemic patients having undergone thyroid surgery were collected. Specimens from parathyroid Ca and metastasis were sampled from the central portion of the tumours to avoid the contamination of parathyroid tissue with adjacent non-parathyroid tissue. Four parathyroid Ca have been previously described (Guarnieri et al. 2008 , Corbetta et al. 2010 . To avoid thyroid tissue contamination, normal parathyroid specimens were microdissected from paraffin-embedded sections of thyroid samples using a LMD6000 instrument (Leica Microsystems, Milan, Italy) . Histologic classification of parathyroid Ca was established according to WHO-published guidelines (Bondenson et al. 2004) . In all patients, fasting serum total calcium, phosphate and creatinine were measured by a multichannel autoanalyser. Intact PTH was determined by a chemiluminescent immunoassay (Nichols Advantage, Nichols Institute Diagnostics, San Clemente, CA, USA). Clinical data of parathyroid Ad are described in Table 1 , whereas information about the parathyroid Ca specimens are shown in Table 2 . The analysed secondarisms were brain metastasis from Ca10, lung metastasis from Ca11 and Ca13 and two distinct lymphatic metastases from Ca15 ( Table 2 ). All carcinomatous and adenomatous specimens were from patients with primary hyperparathyroidism. Human term placenta samples were collected from healthy pregnant women (nZ3). The study protocol was approved by the Local Ethics Committee. Informed consent was obtained from all patients.
DNA extraction and CDC73/HRPT2 gene mutations analysis
Genomic DNA (gDNA) was extracted from the peripheral blood and the tumoural specimen of the patients with parathyroid Ca using standard techniques or a QIAamp DNA Mini kit (Qiagen) respectively according to the manufacturer's protocol. DNA samples were directly sequenced for CDC73/HRPT2 gene mutations, as described previously (Cetani et al. 2004 , Guarnieri et al. 2006 . All gene mutations were confirmed on a second independent gDNA extraction. averaged value of normal parathyroids samples as calibrator (1! sample). As cut-off value for differential expression, we set a fold change (FC) of at least 2 . 5.
When we compared sample groups (Ad, Ca or metastatic lesions), the FC was estimated on the median value of the miRNA in the category. All reagents and instruments were from Applied Biosystems.
Copy number variation analysis
TaqMan copy number (CN) assays were used to investigate genomic variation of C19MC and adjacent loci relative to the reference gene RNase P. In particular, we analysed a 152 bp fragment containing nine CpGs localised on chromosome 19 in position 54 151 441-54 151 592. In brief, 360 ng of each sample were treated with bisulphite by EZ-96 DNA Methylation-Gold Kit following the manufacturers' instructions and were PCR amplified using specific primer sets. PCR products were then purified and directly sequenced with the BigDye Terminator kit and 310 Genetic Analyzer (Perkin-Elmer Corp., Applied Biosystems). Then, the methylation status was analysed for the considered DNA locus with two software tools, which furthermore allow verifying bisulphite conversion efficiency: BiQ Analyzer (http://biq-analyzer.bioinf.mpi-inf.mpg.de/) and BISMA (http://biochem.jacobs-university.de/BDPC/ BISMA/). All samples were tested twice in order to confirm the reproducibility of the results. Tables 2 and 3 , see section on supplementary data given at the end of this article). Instead, seven or nine C19MC miRNAs and MIR372 respectively were over-expressed by Ca or metastatic lesions compared with normal parathyroid samples. Globally, the expression profile of the analysed miRNAs clearly distinguished parathyroid Ad from Ca and metastatic disease (PZ0 . 0008; Fig. 2 ). All but one matched metastases (Met10) and primitive parathyroid Ca showed similar miRNA expression patterns (Fig. 2) . Among all analysed miRNAs, MIR517C showed the most significant difference in expression between parathyroid Ad and Ca (PZ0 . 0003; Supplementary Table 2, see section on supplementary data given at the end of this article), and two Ad showed high MIR517C levels comparable with Ca (Ad23 and Ad24; Fig. 3 ). Elevated MIR517C levels (O2 . 5 folds compared with normal glands) categorised carcinomatous samples with respect to Ad (PZ0 . 001, Fisher's exact test) and were significantly correlated with elevated expression of 12 C19MC miRNAs or with MIR371/MIR372 (Fig. 2 and (Fig. 4) .
The C19MC cluster has been documented to be abundant in human placenta. Therefore, we compared the expression levels of the selected miRNAs belonging to C19MC and MIR371-3 clusters in our series of parathyroid samples with three human term placentas. Hierarchical cluster analysis clearly separates parathyroid carcinoma samples and corresponding metastases from adenomas according to the expression levels of C19MC and MIR371-3 miRNAs. Molecular (copy number gain) and epigenetic (C19MC promoter methylation) information of samples are indicated. MIR517C levels (high, H or low, L) were also used as molecular feature to categorise samples. The cluster branch enriched for parathyroid adenomas was also characterised for low MIR517C levels (PZ0 . 0008). Ad, parathyroid adenomas; Ca, carcinomas; Met, metastases; U, hypomethylated C19MC promoter; M, methylated C19MC promoter; A, genomic amplification of the indicated locus. miRNA cluster C19MC in parathyroid tumours . V VAIRA and others 119
In agreement with the literature, we detected high expression of all investigated miRNAs except for MIR526B, MIR523, MIR516-3p, MIR371 and MIR373 ( Supplementary Fig. 1 , see section on supplementary data given at the end of this article). In regard to parathyroid Ca, comparable median expression levels to human placentas could be documented for MIR519D, MIR518E, MIR517C and MIR372 (Supplementary Fig. 1 , see section on supplementary data given at the end of this article).
Genomic amplification of the chr.19q13.41 region is a frequent event in parathyroid tumours
To discern mechanisms underpinning C19MC and MIR371-3 miRNA cluster over-expression in parathyroid Ca, we investigated whether gain in allelic CN of the chr.19q13.41-42 region was involved. We could detect significant gain in CN either in miRNA cluster regions (Hs.7145628 and Hs.7147457 probes; Fig. 1 ) or at a distant position along chr.19q arm (Hs.4008868 probe; Fig. 1 ). Specifically, four out of 21 parathyroid Ad (19%), ten out of 15 Ca (67%) and four out of five matched metastases (80%) showed amplification of the chr.19q13.41-42 locus for at least one probe (PZ0 . 004 by c 2 test). The analysis of DNA CNV by the distal probe showed that the amplification extended through the distal MIR371-3 cluster in one Ad, six Ca and one metastatic lesion (Tables 1  and 2 and Hs.4008868 probes respectively).
As expression levels of MIR517C were representative of general C19MC miRNA expressions (Table 3) 
Figure 3 MIR517C expression levels in parathyroid adenomas (Ad), primitive carcinomas (Ca) and matched metastatic lesions (Met). Data are expressed as fold increase (positive values) or decrease (negative values) on the averaged expression of the miRNA in normal parathyroid glands. Light grey bars, parathyroid adenomas; black bars, parathyroid carcinomas and white bars, matched metastatic lesions. Table 3 MIR517C levels are a valuable indicator of global C19MC and MIR371-3 miRNA expression profiles. MIR517C levels categorised samples at hierarchical cluster analysis (Fig. 2) . The absolute correlation was therefore calculated to reveal microRNAs associated by similarity in expression pattern 
C19MC promoter methylation status in parathyroid tumours
DNA methylation of CpG-rich regions is a key event in epigenetic gene regulation or genomic imprinting. Therefore, we tested the hypothesis that a different epigenetic pattern in the C19MC promoter regulatory region might be related to deregulation of C19MC miRNA expression in parathyroid tumours. Compared with normal parathyroid glands (all methylated), hypomethylation of this CGI was detected in four parathyroid Ad (29%), seven Ca (58%) and four matched metastatic lesions (100%; PZ0 . 01, c 2 test). Gain in CN or hypomethylation was not mutually exclusive. Hypomethylation of the C19MC promoter region was not significantly associated with MIR517C expression levels in parathyroid samples (PZ0 . 2, Fisher's exact test).
Discussion
In this study, we extended previous knowledge about chr.19q13.41-42 miRNA clusters in parathyroid tumourigenesis by analysing the expression of 15 and three miRNAs from C19MC or MIR371-3 clusters in a considerable series of parathyroid neoplastic lesions. This set of miRNAs was chosen according to their genomic location (UCSC Genome Database, Fig. 1 ) and their biological importance, as described previously (Toffanin et al. 2011 , Augello et al. 2012 . Furthermore, to get insight into deregulation of chr.19 miRNA clusters, allelic CNV of 19q13.41-42 locus (Rakheja et al. 2004 , Li et al. 2009a , Rippe et al. 2010 ) and the epigenetic status of C19MC promoter (Tsai et al. 2009 ) were investigated. Importantly, our cohort comprised five matched metastatic lesions of four primitive parathyroid Ca. This sample set allowed us to analyse chr.19 molecular aberration in progressive disease.
The data showed that multiple molecular aberrations occurred in this locus and they are specific for parathyroid Ca or related metastatic lesions discriminating invasive disease from the less aggressive parathyroid tumours, i.e. Ad. In particular, MIR517C was identified as a potential surrogate marker to correctly classify samples in the appropriate diagnostic category. Indeed, MIR517C expression levels in parathyroid Ad were similar to those observed in normal parathyroid glands, whereas elevated MIR517C levels were detected in parathyroid Ca or matched metastases. C19MC and MIR371-3 miRNA clusters were concurrently expressed in parathyroid tumours, with MIR517C levels being significantly associated with MIR371 and MIR372 expression profiles.
MIR517C expression levels were also related to chr.19 copy gain. By contrast, the methylation status of C19MC promoter was not associated with the miRNA levels nor was it mutually exclusive with variation in allelic CN. Nevertheless, our data showed progressive loss of methylation in C19MC promoter moving from parathyroid Ad to parathyroid Ca and metastatic lesions. A similar pattern of acquisition of molecular anomalies was evident from CNV analysis, where the amplification rate of chr.19 loci increased with disease severity. These observations point out that chr.19q13.41-42 region aberrations are an important hallmark of metastatic progression in parathyroid carcinogenesis.
miRNA deregulation has been recently demonstrated to be involved in cancer development. Different profiles of miRNA expression have been previously described in parathyroid Ca compared with normal parathyroid tissues (Corbetta et al. 2010 , Rahbari et al. 2010 , with members of C19MC miRNA being preliminarily region is frequently amplified in parathyroid carcinomas or matched metastases. Copy number variation analysis was performed for three chr.19 genomic regions that spanned C19MC and MIR371-3 miRNA clusters (assay position is depicted in Fig. 1 ). Data are represented as box-whisker diagrams. White boxes represent normal parathyroid samples; black boxes, adenomas; grey boxes, parathyroid identified as up-regulated in parathyroid Ca compared with normal parathyroid glands (Corbetta et al. 2010) .
The C19MC cluster is considered a paternally imprinted 'embryonic' miRNAs cluster, which is expressed in hESCs and rapidly down-regulated during the differentiation process (Lin et al. 2010) . Consistent with the notion that oncogenic miRNAs are highly expressed in ESCs, C19MC miRNAs are silenced in the majority of normal cells (Tsai et al. 2009 ) and overexpressed in a number of human neoplasias. Indeed, C19MC has been found to be abundantly expressed in term placenta (Liang et al. 2007) .
In accordance with the literature, the analysed term placentas displayed high expression levels of all investigated C19MC miRNAs but MIR526B, MIR523 and MIR516-3p. This expression pattern was similar to those detected in parathyroid Ca though differences in over-expression intensities could be documented ( Supplementary Fig. 1 , see section on supplementary data given at the end of this article).
In the present series, one parathyroid Ad (Ad24 ,  Table 1 ) showed high chr.19 miRNAs similar to Ca or term placenta samples and three more Ad showed CN gain in at least one analysed loci (Table 1) . These Ad were clinically characterised by severe PTH hypersecretion and high tumour weight. Moreover, considering parathyroid adenomatous lesions per se, we found that higher MIR517C expression levels were positively correlated with increased tumour weight.
Similar to what was reported for the C19MC cluster, the MIR371-3 cluster has been implicated in malignant growth (Voorhoeve et al. 2006 , Cho et al. 2009 . Interestingly, the MIR371-3 cluster has also been involved in stem cell maintenance or differentiation and its expression has been reported to be specific for hESCs (Suh et al. 2004) . In the present series, MIR371 and MIR372 were significantly upregulated in parathyroid Ca and matched metastases. The observations that both chr.19 miRNA clusters play a role in stem cell maintenance (Li et al. 2009a) , together with the identification in parathyroid tumours of a subpopulation with progenitor features (Corbetta et al. 2009 ), prompt us to speculate that deregulation of these miRNAs may contribute to maintenance of a tumour-associated parathyroid progenitor cell niche.
As previously described for subsets of aggressive neuroectodermal brain tumours (Li et al. 2009a) , or hepatocellular Ca (Toffanin et al. 2011 , Augello et al. 2012 , our results showed that parathyroid Ca also displayed genomic or epigenetic abnormalities in the chr.19q13.41-42 region compared with normal or adenomatous samples. The analysis of CNV at the C19MC locus identified an amplification of this region in two-thirds of parathyroid Ca extending distal to the MIR371-3 cluster in most of the amplified samples. These results are in agreement with the data showing DNA CN alterations by CGH in parathyroid neoplasia, with gains at chromosome 19q in 20% of Ca and about 5% of Ad (Kytola et al. 2000) .
The methylation status of promoter regions has also been analysed in parathyroid tumours (Starker et al. 2011) and frequent hypermethylation of RIZ1/PRDM2, CDKN2A, RASSF1A and APC genes has been reported (Carling et al. 2003 , Juhlin et al. 2010 , Svedlund et al. 2010 .
The C19MC cluster is silenced in most cells by hypermethylation of a distal CpG-rich region localised 17 . 6 kb upstream of the C19MC (Tsai et al. 2009 ). Our analysis of the methylation status in parathyroid tumours showed that the C19MC promoter region was hypomethylated in 29, 58 or 100% of Ad, Ca or metastatic samples, respectively, therefore being a marker of aggressive parathyroid tumours. Nonetheless, hypomethylation and CN amplification of the C19MC cluster were not mutually exclusive. Admittedly, CN amplification and hypomethylation were not unequivocally associated with MIR517C up-regulation, discrepant data being observed in a small number of tumours.
In conclusion, this study showed that C19MC and MIR371-3 miRNA clusters were reactivated in a consistent proportion of parathyroid Ca possibly due to genomic gains of chr.19 loci. The data here presented pointed towards an oncogenic role of MIR517C in parathyroid tumourigenesis and deregulation of this cluster might contribute to survival and growth of cell populations with stem/progenitor function. Importantly, we evidenced that molecular aberration in chr.19q13.41-42 region is a marker of aggressive tumour in parathyroid neoplasia that could be helpful in its diagnostic management. Further understanding of function and regulation of these miRNAs and their target genes might provide the basis for identifying novel therapeutic approaches.
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